The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. / Thomsen, Mads Norvin; Skytte, Mads Juul; Astrup, Arne; Deacon, Carolyn F; Holst, Jens Juul; Madsbad, Sten; Krarup, Thure; Haugaard, Steen Bendix; Samkani, Amirsalar.

In: Clinical Nutrition ESPEN, Vol. 39, 2020, p. 46-52.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Thomsen, MN, Skytte, MJ, Astrup, A, Deacon, CF, Holst, JJ, Madsbad, S, Krarup, T, Haugaard, SB & Samkani, A 2020, 'The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study', Clinical Nutrition ESPEN, vol. 39, pp. 46-52. https://doi.org/10.1016/j.clnesp.2020.07.002

APA

Thomsen, M. N., Skytte, M. J., Astrup, A., Deacon, C. F., Holst, J. J., Madsbad, S., Krarup, T., Haugaard, S. B., & Samkani, A. (2020). The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. Clinical Nutrition ESPEN, 39, 46-52. https://doi.org/10.1016/j.clnesp.2020.07.002

Vancouver

Thomsen MN, Skytte MJ, Astrup A, Deacon CF, Holst JJ, Madsbad S et al. The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. Clinical Nutrition ESPEN. 2020;39:46-52. https://doi.org/10.1016/j.clnesp.2020.07.002

Author

Thomsen, Mads Norvin ; Skytte, Mads Juul ; Astrup, Arne ; Deacon, Carolyn F ; Holst, Jens Juul ; Madsbad, Sten ; Krarup, Thure ; Haugaard, Steen Bendix ; Samkani, Amirsalar. / The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. In: Clinical Nutrition ESPEN. 2020 ; Vol. 39. pp. 46-52.

Bibtex

@article{56cd71e3b542487ba8cda5a8f4a24266,
title = "The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study",
abstract = "Background & aims: High glycaemic variability (GV) is associated with late complications in type 2 diabetes (T2D). We hypothesised that a carbohydrate-reduced high-protein (CRHP) diet would reduce GV acutely in patients with T2D compared with a conventional diabetes (CD) diet. Methods: In this controlled, randomised crossover study, 16 patients with metformin-treated T2D (median (IQR) age: 64.0 (58.8–68.0) years; HbA1c: 47 (43–57) mmol/mol; duration of T2D: 5.5 (2.8–10.3) years) were assigned to an energy-matched CRHP diet and CD diet (31E%/54E% carbohydrate, 29E%/16E% protein and 40E%/30E% fat, respectively) for two separate 48-h intervention periods. Interstitial continuous glucose monitoring (CGM) was performed to assess accepted measures of glycaemic variability, i.e. standard deviation (SD) around the sensor glucose level; coefficient of variation in percent (CV); mean amplitude of glucose excursions (MAGE); continuous overlapping net glycaemic action (CONGA1, CONGA4) of observations 1 and 4 h apart; and mean absolute glucose (MAG) change. Results: All indices of glycaemic variability (mean ± SD) were significantly reduced during CRHP diet compared with CD diet; including SD (1.0 ± 0.3 (CRHP) vs 1.6 ± 0.5 mmol/L (CD)), CV (12.3 ± 3.8 vs 19.3 ± 5.5%), MAGE (2.3 ± 0.9 vs 4.2 ± 1.3 mmol/L), CONGA1 (0.8 ± 0.3 vs 1.5 ± 0.4 mmol/L), CONGA4 (1.4 ± 0.5 vs 2.5 ± 0.8 mmol/L), and MAG change (0.9 ± 0.3 vs 1.4 ± 0.4 mmol/L/h) (p < 0.001 for all). Compared with the CD diet, the CRHP diet improved the diurnal glucose profile by reducing 24-h mean sensor glucose (7.7 ± 1.6 vs 8.6 ± 2.0 mmol/L). Conclusions: In T2D patients treated with diet and metformin, two days of iso-energetic replacement of dietary carbohydrates by protein and fat reduced all indices of glycaemic variability by 36%–45% when compared with a conventional diabetes diet. These data may support reduction of carbohydrates as dietary advice for T2D patients. Clinicaltrials.gov identifier: NCT02472951.",
keywords = "Continuous glucose monitoring, Glycaemic variability, Low-carbohydrate diet, Type 2 diabetes",
author = "Thomsen, {Mads Norvin} and Skytte, {Mads Juul} and Arne Astrup and Deacon, {Carolyn F} and Holst, {Jens Juul} and Sten Madsbad and Thure Krarup and Haugaard, {Steen Bendix} and Amirsalar Samkani",
note = "CURIS 2020 NEXS 271",
year = "2020",
doi = "10.1016/j.clnesp.2020.07.002",
language = "English",
volume = "39",
pages = "46--52",
journal = "Clinical Nutrition ESPEN",
issn = "2405-4577",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study

AU - Thomsen, Mads Norvin

AU - Skytte, Mads Juul

AU - Astrup, Arne

AU - Deacon, Carolyn F

AU - Holst, Jens Juul

AU - Madsbad, Sten

AU - Krarup, Thure

AU - Haugaard, Steen Bendix

AU - Samkani, Amirsalar

N1 - CURIS 2020 NEXS 271

PY - 2020

Y1 - 2020

N2 - Background & aims: High glycaemic variability (GV) is associated with late complications in type 2 diabetes (T2D). We hypothesised that a carbohydrate-reduced high-protein (CRHP) diet would reduce GV acutely in patients with T2D compared with a conventional diabetes (CD) diet. Methods: In this controlled, randomised crossover study, 16 patients with metformin-treated T2D (median (IQR) age: 64.0 (58.8–68.0) years; HbA1c: 47 (43–57) mmol/mol; duration of T2D: 5.5 (2.8–10.3) years) were assigned to an energy-matched CRHP diet and CD diet (31E%/54E% carbohydrate, 29E%/16E% protein and 40E%/30E% fat, respectively) for two separate 48-h intervention periods. Interstitial continuous glucose monitoring (CGM) was performed to assess accepted measures of glycaemic variability, i.e. standard deviation (SD) around the sensor glucose level; coefficient of variation in percent (CV); mean amplitude of glucose excursions (MAGE); continuous overlapping net glycaemic action (CONGA1, CONGA4) of observations 1 and 4 h apart; and mean absolute glucose (MAG) change. Results: All indices of glycaemic variability (mean ± SD) were significantly reduced during CRHP diet compared with CD diet; including SD (1.0 ± 0.3 (CRHP) vs 1.6 ± 0.5 mmol/L (CD)), CV (12.3 ± 3.8 vs 19.3 ± 5.5%), MAGE (2.3 ± 0.9 vs 4.2 ± 1.3 mmol/L), CONGA1 (0.8 ± 0.3 vs 1.5 ± 0.4 mmol/L), CONGA4 (1.4 ± 0.5 vs 2.5 ± 0.8 mmol/L), and MAG change (0.9 ± 0.3 vs 1.4 ± 0.4 mmol/L/h) (p < 0.001 for all). Compared with the CD diet, the CRHP diet improved the diurnal glucose profile by reducing 24-h mean sensor glucose (7.7 ± 1.6 vs 8.6 ± 2.0 mmol/L). Conclusions: In T2D patients treated with diet and metformin, two days of iso-energetic replacement of dietary carbohydrates by protein and fat reduced all indices of glycaemic variability by 36%–45% when compared with a conventional diabetes diet. These data may support reduction of carbohydrates as dietary advice for T2D patients. Clinicaltrials.gov identifier: NCT02472951.

AB - Background & aims: High glycaemic variability (GV) is associated with late complications in type 2 diabetes (T2D). We hypothesised that a carbohydrate-reduced high-protein (CRHP) diet would reduce GV acutely in patients with T2D compared with a conventional diabetes (CD) diet. Methods: In this controlled, randomised crossover study, 16 patients with metformin-treated T2D (median (IQR) age: 64.0 (58.8–68.0) years; HbA1c: 47 (43–57) mmol/mol; duration of T2D: 5.5 (2.8–10.3) years) were assigned to an energy-matched CRHP diet and CD diet (31E%/54E% carbohydrate, 29E%/16E% protein and 40E%/30E% fat, respectively) for two separate 48-h intervention periods. Interstitial continuous glucose monitoring (CGM) was performed to assess accepted measures of glycaemic variability, i.e. standard deviation (SD) around the sensor glucose level; coefficient of variation in percent (CV); mean amplitude of glucose excursions (MAGE); continuous overlapping net glycaemic action (CONGA1, CONGA4) of observations 1 and 4 h apart; and mean absolute glucose (MAG) change. Results: All indices of glycaemic variability (mean ± SD) were significantly reduced during CRHP diet compared with CD diet; including SD (1.0 ± 0.3 (CRHP) vs 1.6 ± 0.5 mmol/L (CD)), CV (12.3 ± 3.8 vs 19.3 ± 5.5%), MAGE (2.3 ± 0.9 vs 4.2 ± 1.3 mmol/L), CONGA1 (0.8 ± 0.3 vs 1.5 ± 0.4 mmol/L), CONGA4 (1.4 ± 0.5 vs 2.5 ± 0.8 mmol/L), and MAG change (0.9 ± 0.3 vs 1.4 ± 0.4 mmol/L/h) (p < 0.001 for all). Compared with the CD diet, the CRHP diet improved the diurnal glucose profile by reducing 24-h mean sensor glucose (7.7 ± 1.6 vs 8.6 ± 2.0 mmol/L). Conclusions: In T2D patients treated with diet and metformin, two days of iso-energetic replacement of dietary carbohydrates by protein and fat reduced all indices of glycaemic variability by 36%–45% when compared with a conventional diabetes diet. These data may support reduction of carbohydrates as dietary advice for T2D patients. Clinicaltrials.gov identifier: NCT02472951.

KW - Continuous glucose monitoring

KW - Glycaemic variability

KW - Low-carbohydrate diet

KW - Type 2 diabetes

U2 - 10.1016/j.clnesp.2020.07.002

DO - 10.1016/j.clnesp.2020.07.002

M3 - Journal article

C2 - 32859328

AN - SCOPUS:85088952095

VL - 39

SP - 46

EP - 52

JO - Clinical Nutrition ESPEN

JF - Clinical Nutrition ESPEN

SN - 2405-4577

ER -

ID: 247491857